Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Myung Ah Lee et al.|NEJM Evidence|2022Cited by 1.1k
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trialsMairéad G. McNamara, Juan W. Valle|BMC Cancer|2017Cited by 25
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trialsZainul Abedin Kapacee, Mairéad G. McNamara, Jennifer J. Knox et al.|Medical Oncology|2020Cited by 15